JPRN-UMIN000039783招募中2 期
A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancer - Phase II study of XELOXIRI+Bevacizumab
Sapporo Medical University School of Medicine0 个研究点目标入组 47 人开始时间: 2020年3月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Need to drain malignant fluid. 2. With a history of allergic response to Fluorouracil or Levofolinate calcium or Platinium. 3. Pregnant or lactating women or women of childbearing potential. 4. Uncontrolled infection. 5. Evidence of interstinal lung disease, or pulmonary fibrosis. 6. Clinically significant (i.e. active) cardiovascular disease or past or current history (within the last 1 year) of myocardial infarction. 7. Uncontrollable ulcer indigestive tract. 8. Radiological evidence of CNS metastases or brain cancer. 9. Complication of cerebrovascular disease or symptoms within 1 year. 10. Any surgical treatments within 4 weeks. 11. Administering antithrombotic drug within 10 days. Need to administrate or having anti-platelets therapy 12. Multiple primary cancers within 5 years. 13. Other conditions not suitable for this study.
研究者
相似试验
已完成
不适用
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
已完成
不适用
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)unresectable/advanced gastric cancerJPRN-UMIN000016256Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)12
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
进行中（未招募）
不适用
Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer - BOXERMetastatic colorectal adenocarcinoma with metastases involving the liver onlyMedDRA version: 8.1Level: PTClassification code 10010035Term: Colorectal cancer stage IVEUCTR2005-004505-29-GBRoyal Marsden NHS Trust46
已完成
2 期
P II study of CapeOX therapy for small intestinal cancerunresectable or recurrent small bowel adenocarcinoma with no prior treatmentJPRN-jRCTs041180011Yasui Hirofumi17